VivoSeq
Nephrology

Lupus Nephritis

117

Pipeline Programs↗

42

Active Trials↗

57

Companies Involved↗

Lupus Nephritis is a highly competitive landscape with 117 programs across 57 companies. The most active players are Regeneron, Translational Biosciences, Johnson & Johnson. 19 therapies are approved with 31 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

74/100

Pipeline Velocity

34/100

Mech. Concentration

7/100

Completion Rate

58/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Regeneron logo

Regeneron

2 programs

Phase 1T

Translational Biosciences

1 program

Phase 1Johnson & Johnson logo

Johnson & Johnson

4 programs

Phase 2Amgen logo

Amgen

3 programs

Phase 2K

Kyverna Therapeutics

2 programs

Phase 2Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical18

Belimumab

Glaxo Dba Glaxosmithkline

Tacrolimus

Veloxis Pharmaceuticals

Losartan

Organon and Co

Tacrolimus+mycophenolate Mofetil

Zhi-Hong Liu, M.D.

Hydroxychloroquine

Alnylam Pharmaceuticals

Phase 111

Ixazomib

Takeda

GSK4482820

GSK

Odronextamab

Regeneron

Vonsetamig

Regeneron

Felzartamab

Biogen

Phase 238

Curcumin

Merck & Co.

Zanubrutinib

BeOne Medicines

Guselkumab

Johnson & Johnson

Efgartigimod

Argenx

Daratumumab

Johnson & Johnson

Phase 331

Mycophenolate Sodium

Novartis

Pembrolizumab

Merck & Co.

Voclosporin

Aurinia Pharmaceuticals

Anifrolumab

AstraZeneca

Atacicept

EMD Serono

Approved19

Prednisolone

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Azathioprine

Legacy Health System

Mycophenolate Mofetil

Roche

Cyclophosphamide

Baxter Healthcare Corporation

Cyclosporine

Novartis

Analysis

Modality Breakdown

74%

Small molecule

105 of 142 classified programs — the dominant modality here.

26%ALL OTHERSMonoclonal antibody1712%Cell therapy1410%Protein / enzyme64%

Small molecule leads; the ring shows all 142 classified programs, each share of the total. Modality classified for 97% of 155 pipeline programs.

Analysis

Trial Status

159

clinical trials

Completed54 · 34%
Terminated28 · 18%
Recruiting27 · 17%
Unknown status24 · 15%
Withdrawn11 · 7%
Active, not recruiting9 · 6%
Other6 · 4%

Clinical Trials

Trial Activity

159 trials

Phase IIa Study for IPG11406 in Patients With Lupus Nephritis
Recruiting·NNanjing Immunophage Biotech Co., Ltd·Phase 1/2·NCT06717815·36 enrolled
Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease
Recruiting·TTongji Hospital·Phase 1·NCT06497361·30 enrolled
Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells
Recruiting·RRed de Terapia Celular·Phase 2·NCT03673748·20 enrolled
The Effect of Mycophenolate Mofetil and Cyclophosphamide on the Lymphocyte Subsets in Patients With Proliferative Lupus Nephritis
Recruiting·TThe University of Hong Kong·N/A·NCT02954939·50 enrolled
Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF
Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT04702256·196 enrolled
RY_SW01 Cell Injection Therapy in Active Lupus Nephritis
Recruiting·—·Phase 2·NCT06058078·60 enrolled
Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease
Recruiting·TTongji Hospital·Phase 1·NCT06497387·30 enrolled
A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment
Recruiting·VViatris Innovation GmbH·Phase 3·NCT07201129·300 enrolled
Minimizing Glucocorticoid Administration in Patients With Proliferative Lupus Nephritis
Recruiting·IInstitutul Clinic Fundeni·Phase 4·NCT05207358·30 enrolled
A Study of Telitacicept in Lupus Nephritis
Recruiting·RRemeGen Co., Ltd.·Phase 2·NCT05680480·120 enrolled
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
Recruiting·Novartis logoNovartis·Phase 3·NCT05126277·462 enrolled
A Phase II Clinical Study on the Efficacy and Safety of SHR-2173 Injection in the Treatment of Patients With Active Lupus Nephritis
Recruiting·Guangdong Hengrui Pharmaceutical Co., Ltd logoGuangdong Hengrui Pharmaceutical Co., Ltd·Phase 2·NCT07229742·51 enrolled
The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment
Recruiting·NNanjing University School of Medicine·Phase 2·NCT07340463·50 enrolled
CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis
Recruiting·—·Phase 1·NCT06785519·9 enrolled
Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells
Recruiting·—·N/A·NCT06277427·24 enrolled
Page 1 of 11

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)